First-Line Antiemetic for Pregnancy
The first-line antiemetics for nausea and vomiting of pregnancy are antihistamines (H1 receptor antagonists such as promethazine, cyclizine), phenothiazines (such as prochlorperazine), or doxylamine-pyridoxine combination (Xonvea®), all of which have Grade A evidence supporting their safety and efficacy. 1
Recommended Treatment Algorithm
First-Line Options (Choose One):
- Antihistamines (H1 antagonists): Promethazine, cyclizine, cinnarizine, or dimenhydrinate
- Phenothiazines: Prochlorperazine, chlorpromazine, or perphenazine
- Doxylamine-pyridoxine combination (Xonvea®)
- Pyridoxine (Vitamin B6) alone can be used for milder symptoms
The 2024 BJOG Green-Top Guideline explicitly states these agents should be prescribed initially when required for nausea and vomiting of pregnancy (NVP) and hyperemesis gravidarum (HG), based on Cochrane review evidence showing no increased risk of congenital malformations or other adverse pregnancy outcomes 1. The choice among these first-line agents is based predominantly on safety data rather than efficacy differences, as no clear data supports one class being more effective than others 1.
Second-Line Options (If First-Line Fails):
Ondansetron is the recommended second-line agent and should not be discouraged if first-line antiemetics are ineffective 1. Women can be reassured that while there is a very small increase in absolute risk of orofacial clefting (from 11 cases per 10,000 births to 14 cases per 10,000 births), this must be balanced against the risks of poorly managed hyperemesis gravidarum 1. Data from over 97,000 first-trimester exposures show no overall increase in malformation rates 1.
Metoclopramide is also safe and effective as second-line therapy, though it carries risk of extrapyramidal effects and should be given intravenously by slow bolus over at least 3 minutes to minimize these risks 1.
Important Clinical Considerations
Combination Therapy:
If single-agent therapy fails, combinations of different antiemetic classes should be used 1. The stepwise approach allows escalation based on symptom severity and response.
Severity Assessment:
Use validated tools like the Pregnancy-Unique Quantification of Emesis (PUQE) score to objectively classify severity and guide treatment decisions 1. Do not use ketonuria to assess severity or dehydration—this is Grade A evidence that it is not a reliable indicator 1.
Common Pitfall:
The guideline emphasizes that delayed-release formulations are more effective than immediate-release preparations, as they create stable blood levels 1. Always ask about previous adverse reactions to antiemetics before prescribing 1.
Safety Profile:
All first-line agents have extensive safety data with no increased teratogenicity risk. The evidence base includes large cohort studies and systematic reviews confirming their safety profile during pregnancy 1, 2.